HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) is marking Eczema Awareness Month by underscoring the growing body of clinical evidence supporting its XTRAC® Excimer Laser (308 nm) as a safe, effective treatment for localized atopic dermatitis, the most common form of eczema. The announcement follows the American Medical Association’s recent expansion of excimer laser indications to include inflammatory and autoimmune skin diseases, opening the door for broader Medicare, Medicaid, and private payer reimbursement.
“Atopic dermatitis affects millions of Americans and significantly impacts quality of life,” said Dr. Dolev Rafaeli, CEO of STRATA. “Excimer laser treatment continues to capture market share among dermatologists because it remains effective, safe, and durable. Providers and advocacy groups have long sought expanded reimbursement, and with these updates, the therapy can reach more patients.”
Atopic dermatitis affects an estimated 9.6 million children and 16.5 million adults in the United States. Beyond visible symptoms such as pain, itching, and fissures, the condition can disrupt sleep, work, and daily activities. Current treatment options remain limited, particularly for patients with localized and difficult-to-treat cases.
“The excimer laser is one of our most effective treatments for localized eczema,” said Dr. Mark G. Lebwohl, M.D., Dean for Clinical Therapeutics and Chairman Emeritus of Dermatology at the Icahn School of Medicine at Mount Sinai, a leading researcher in phototherapy.
Peer-reviewed studies spanning nearly two decades support the therapy. Research has demonstrated significant reductions in itching, inflammation, and disease severity, with durable remission periods and favorable safety profiles compared to standard steroid treatments. Studies also highlight excimer laser’s effectiveness for chronic hand and foot eczema, areas often resistant to conventional therapies.
The XTRAC® system offers targeted treatment that spares healthy tissue, reduces UV exposure compared to full-body phototherapy, and provides long-lasting remission with shorter treatment regimens. Importantly, it allows patients to minimize long-term steroid use.
STRATA’s continued emphasis on excimer laser technology reflects its strategic focus on personalized dermatologic care, supported by more than 400 clinical publications and a track record of safety across multiple indications.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.